Paperbase

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection

Queval, Christophe J. Song, Ok-Ryul Deboosere, Nathalie Delorme, Vincent Debrie, Anne-Sophie Iantomasi, Raffaella Veyron-Churlet, Romain Jouny, Samuel Redhage, Keely Deloison, Gaspard Baulard, Alain Chamaillard, Mathias Locht, Camille Brodin, Priscille

Scientific reports, 2016

https://doi.org/10.1038/srep29297

Vincent Delorme

Delorme Vincent

ORCID: 0000-0001-5235-7069

Discovery of thienothiazolocarboxamide analogues as novel anti-tubercular agent. 10.1016/j.bmc.2020.115797

Drug Discovery Platform Targeting M. tuberculosis with Human Embryonic Stem Cell-Derived Macrophages. 10.1016/j.stemcr.2019.10.002

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. 10.1016/j.bioorg.2018.08.025

Molecular Targets Related Drug Resistance Mechanisms in MDR-, XDR-, and TDR-Mycobacterium tuberculosis Strains. 10.3389/fcimb.2018.00114

Publisher Correction: Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-018-25177-2

Mycobacterium tuberculosis Infection and Innate Responses in a New Model of Lung Alveolar Macrophages. 10.3389/fimmu.2018.00438

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis. 10.1128/aac.02637-16

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities. 10.1177/1087057116675887

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

Supported inhibitor for fishing lipases in complex biological media and mass spectrometry identification. 10.1016/j.biochi.2014.07.015

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Analysis of the discriminative inhibition of mammalian digestive lipases by 3-phenyl substituted 1,3,4-oxadiazol-2(3H)-ones. 10.1016/j.ejmech.2012.10.040

MmPPOX inhibits Mycobacterium tuberculosis lipolytic enzymes belonging to the hormone-sensitive lipase family and alters mycobacterial growth. 10.1371/journal.pone.0046493

Inhibition of phospholipase A1, lipase and galactolipase activities of pancreatic lipase-related protein 2 by methyl arachidonyl fluorophosphonate (MAFP). 10.1016/j.bbalip.2012.07.014

Effects of surfactants on lipase structure, activity, and inhibition. 10.1007/s11095-010-0362-9

CO2 binding by dynamic combinatorial chemistry: an environmental selection. 10.1021/ja909975q

Two cutinase-like proteins secreted by Mycobacterium tuberculosis show very different lipolytic activities reflecting their physiological function. 10.1096/fj.09-144766

Synthesis and kinetic evaluation of cyclophostin and cyclipostins phosphonate analogs as selective and potent inhibitors of microbial lipases. 10.1021/jm301216x

Phenotypic Screening for Drug Discovery in Tuberculosis https://doi.org/10.1039/9781839160721-00198

Camille Locht

Locht Camille

ORCID: 0000-0001-7295-7336

HBHA-Induced Polycytotoxic CD4+ T Lymphocytes Are Associated with the Control of Mycobacterium tuberculosis Infection in Humans 10.4049/jimmunol.1800840

Distinct virulence ranges for infection of mice by Bordetella pertussis revealed by engineering of the sensor-kinase BvgS 10.1371/journal.pone.0204861

Non-specific Effects of Live Attenuated Pertussis Vaccine Against Heterologous Infectious and Inflammatory Diseases 10.3389/fimmu.2018.02872

IL-17-dependent SIgA-mediated protection against nasal Bordetella pertussis infection by live attenuated BPZE1 vaccine 10.1038/s41385-018-0073-9

Rv0613c/MSMEG_1285 Interacts with HBHA and Mediates Its Proper Cell-Surface Exposure in Mycobacteria 10.3390/ijms19061673

Tuberculin skin test reaction is related to memory, but not naive CD4+ T cell responses to mycobacterial stimuli in BCG-vaccinated young adults 10.1016/j.vaccine.2018.05.068

Diversion of complement-mediated killing by Bordetella 10.1016/j.micinf.2018.02.002

TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development 10.3389/fimmu.2017.01203

Characterization of a Bvg-regulated fatty acid methyl-transferase in Bordetella pertussis 10.1371/journal.pone.0176396

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

In vivo imaging of bacterial colonization of the lower respiratory tract in a baboon model of Bordetella pertussis infection and transmission 10.1038/s41598-018-30896-7

Primary transcriptome analysis reveals importance of IS elements for the shaping of the transcriptional landscape of Bordetella pertussis 10.1080/15476286.2018.1462655

Bordetella pertussis pertactin knock-out strains reveal immunomodulatory properties of this virulence factor 10.1038/s41426-018-0039-8

Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3 10.1016/j.vaccine.2018.02.017

Will we have new pertussis vaccines? 10.1016/j.vaccine.2017.11.055

Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women 10.1016/j.vaccine.2018.01.059

Conformational Changes of an Interdomain Linker Mediate Mechanical Signal Transmission in Sensor Kinase BvgS 10.1128/JB.00114-17

Coiled-Coil Antagonism Regulates Activity of Venus Flytrap-Domain-Containing Sensor Kinases of the BvgS Family 10.1128/mBio.02052-17

The Role of Mucosal Immunity in Pertussis 10.3389/fimmu.2018.03068

Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection 10.1093/infdis/jix254

BCG and protection against inflammatory and auto-immune diseases 10.1080/14760584.2017.1333906

Age-Stratified T Cell Responses in Children Infected with Mycobacterium tuberculosis 10.3389/fimmu.2017.01059

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development 10.1128/CVI.00388-16

Erratum for Carbonetti et al., "Highlights of the 11th International Bordetella Symposium: from Basic Biology to Vaccine Development" 10.1128/CVI.00071-17

Human isotype-dependent inhibitory antibody responses against Mycobacterium tuberculosis 10.15252/emmm.201606330

Live pertussis vaccines: will they protect against carriage and spread of pertussis? 10.1016/j.cmi.2016.05.029

The multifaceted RisA regulon of Bordetella pertussis 10.1038/srep32774

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Added Value of Long-Term Cytokine Release Assays to Detect Mycobacterium tuberculosis Infection in HIV-Infected Subjects in Uganda 10.1097/QAI.0000000000000980

[Tuberculosis, a story still relevant] 10.1051/medsci/20163206001

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

Pertussis: Where did we go wrong and what can we do about it? 10.1016/j.jinf.2016.04.020

Pertussis: acellular, whole-cell, new vaccines, what to choose? 10.1586/14760584.2016.1161511

Balance between Coiled-Coil Stability and Dynamics Regulates Activity of BvgS Sensor Kinase in Bordetella 10.1128/mBio.02089-15

Reciprocal interference of maternal and infant immunization in protection against pertussis 10.1016/j.vaccine.2016.01.011

Signal transduction by BvgS sensor kinase. Binding of modulator nicotinate affects the conformation and dynamics of the entire periplasmic moiety 10.1074/jbc.A115.655720

Integrating knowledge of Mycobacterium tuberculosis pathogenesis for the design of better vaccines 10.1586/14760584.2015.1102638

Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated Adults 10.1155/2015/359153

Lower Pre-Treatment T Cell Activation in Early- and Late-Onset Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome 10.1371/journal.pone.0133924

Dynamic interplay of membrane-proximal POTRA domain and conserved loop L6 in Omp85 transporter FhaC 10.1111/mmi.13137

Signal Transduction by BvgS Sensor Kinase: BINDING OF MODULATOR NICOTINATE AFFECTS THE CONFORMATION AND DYNAMICS OF THE ENTIRE PERIPLASMIC MOIETY 10.1074/jbc.M115.655720

Virulence regulation with Venus flytrap domains: structure and function of the periplasmic moiety of the sensor-kinase BvgS 10.1371/journal.ppat.1004700

Investigating pertussis toxin and its impact on vaccination 10.2217/fmb.14.123

Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube 10.1186/s12879-015-0796-0

Early cellular immune response to a new candidate mycobacterial vaccine antigen in childhood tuberculosis 10.1016/j.vaccine.2014.12.011

Unconventional, adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine 10.1189/jlb.3a0315-101r

Translocation path of a substrate protein through its Omp85 transporter 10.1038/ncomms6271

Antigen-specific interferon-gamma responses and innate cytokine balance in TB-IRIS 10.1371/journal.pone.0113101

HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis 10.1016/j.vaccine.2014.09.024

Toward Understanding the Essence of Post-Translational Modifications for the Mycobacterium tuberculosis Immunoproteome 10.3389/fimmu.2014.00361

Live attenuated B. pertussis BPZE1 rescues the immune functions of Respiratory Syncytial virus infected human dendritic cells by promoting Th1/Th17 responses 10.1371/journal.pone.0100166

Live attenuated vaccines against pertussis 10.1586/14760584.2014.942222

Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutinin 10.1016/j.micinf.2014.04.003

Conformational dynamics of protein transporter FhaC: large-scale motions of plug helix 10.1111/mmi.12585

B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial 10.1016/j.vaccine.2014.04.048

Possible options for new pertussis vaccines 10.1093/infdis/jit531

A phase I clinical study of a live attenuated Bordetella pertussis vaccine--BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers 10.1371/journal.pone.0083449

Mucosal delivery of antigen-coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice 10.1002/eji.201343887

Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae 10.1128/CVI.00134-14

Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice 10.1016/j.vaccine.2014.06.019

Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis 10.1128/CVI.00651-13

LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients 10.1371/journal.pone.0081856

Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism 10.1164/rccm.201307-1227OC

Protective role of adenylate cyclase in the context of a live pertussis vaccine candidate 10.1016/j.micinf.2013.10.002

Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination 10.1016/j.vaccine.2013.10.056

Heparin-binding haemagglutinin, a new tool for the detection of latent Mycobacterium tuberculosis infection in hemodialysis patients 10.1371/journal.pone.0071088

Novel feature of Mycobacterium avium subsp. paratuberculosis, highlighted by characterization of the heparin-binding hemagglutinin adhesin 10.1128/JB.00671-13

Characterization of the PAS domain in the sensor-kinase BvgS: mechanical role in signal transmission 10.1186/1471-2180-13-172

Modulation of the complement system in monocytes contributes to tuberculosis-associated immune reconstitution inflammatory syndrome 10.1097/qad.0b013e328361648b

The role of monocytes in the development of Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome 10.1016/j.imbio.2013.07.004

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e 10.1371/journal.pone.0059198

Purification of native HBHA from Mycobacterium avium subsp. paratuberculosis 10.1186/1756-0500-6-55

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis 10.1038/ng.2517

Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose 10.1016/j.vaccine.2013.02.004

Low prevalence of vitamin D deficiency in Ugandan HIV-infected patients with and without tuberculosis 10.5588/ijtld.11.0146

Broad heparin-binding haemagglutinin-specific cytokine and chemokine response in infants following Mycobacterium bovis BCG vaccination 10.1002/eji.201142297

Risk stratification of latent tuberculosis defined by combined interferon gamma release assays 10.1371/journal.pone.0043285

Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models 10.1111/j.1398-9995.2012.02884.x

Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice 10.1016/j.vaccine.2012.07.005

New pertussis vaccination approaches: en route to protect newborns? 10.1111/j.1574-695x.2012.00988.x

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis 10.1021/jm300377g

Differential contribution of the repeats to heparin binding of HBHA, a major adhesin of Mycobacterium tuberculosis 10.1371/journal.pone.0032421

Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection 10.3851/imp2108

Both CD4⁺ and CD8⁺ lymphocytes participate in the IFN-γ response to filamentous hemagglutinin from Bordetella pertussis in infants, children, and adults 10.1155/2012/795958

Structural activation of the transcriptional repressor EthR from Mycobacterium tuberculosis by single amino acid change mimicking natural and synthetic ligands 10.1093/nar/gkr1113

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors 10.1021/jm200825u

The ins and outs of pertussis toxin 10.1111/j.1742-4658.2011.08237.x

Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome 10.1097/qai.0b013e31823801de

Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy 10.1097/qai.0b013e3182255dc2

[New antituberculosis vaccines] 10.1016/j.arcped.2011.05.003

Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e 10.1016/j.vaccine.2011.05.052

Recombinant HBHA boosting effect on BCG-induced immunity against Mycobacterium tuberculosis infection 10.1155/2011/730702

Substrate recognition by the POTRA domains of TpsB transporter FhaC 10.1111/j.1365-2958.2011.07680.x

Membrane-associated DegP in Bordetella chaperones a repeat-rich secretory protein 10.1111/j.1365-2958.2011.07672.x

Detection of small RNAs in Bordetella pertussis and identification of a novel repeated genetic element 10.1186/1471-2164-12-207

The forest behind the tree: phylogenetic exploration of a dominant Mycobacterium tuberculosis strain lineage from a high tuberculosis burden country 10.1371/journal.pone.0018256

Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response 10.4049/jimmunol.1003765

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors 10.1021/jm200076a

Characterization of the Mycobacterium avium subsp. paratuberculosis laminin-binding/histone-like protein (Lbp/Hlp) which reacts with sera from patients with Crohn's disease 10.1016/j.micinf.2011.02.002

Chips from chips: application to the study of antibody responses to methylated proteins 10.1021/pr100707t

Exploring drug target flexibility using in situ click chemistry: application to a mycobacterial transcriptional regulator 10.1021/cb100177g

Functional importance of a conserved sequence motif in FhaC, a prototypic member of the TpsB/Omp85 superfamily 10.1111/j.1742-4658.2010.07881.x

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1 10.1016/j.vaccine.2010.08.017

Report of the 2nd "French Clinical Vaccinology Meeting Jean-Gerard Guillet": immunization and respiratory diseases 10.1016/j.vaccine.2010.07.038

Periplasmic domain of the sensor-kinase BvgS reveals a new paradigm for the Venus flytrap mechanism 10.1073/pnas.1006267107

Boosting BCG to protect against TB 10.1586/ers.10.25

Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm 10.1128/JVI.02542-09

Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis 10.1016/j.vaccine.2010.04.062

T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis 10.1371/journal.pone.0010178

Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model 10.1111/j.1365-2222.2010.03459.x

Heparin-binding, hemagglutinin-specific IFN-gamma synthesis at the site of infection during active tuberculosis in humans 10.1164/rccm.201001-0083oc

Impact of HIV infection on the recurrence of tuberculosis in South India 10.1086/650528

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice 10.1128/CVI.00322-09

Cellular immune responses of preterm infants after vaccination with whole-cell or acellular pertussis vaccines 10.1128/CVI.00328-09

Correction: Molecular Evolution of the Two-Component System BvgAS Involved in Virulence Regulation in Bordetella 10.1371/annotation/ae7f86ff-0aca-4411-aed3-3eeea9303abb

Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response in vaccinated infants 10.1128/CVI.00314-09

In situ chemical modification of peptide microarrays: application to the study of the antibody responses to methylated antigens 10.1007/978-1-60761-845-4_11

Molecular evolution of the two-component system BvgAS involved in virulence regulation in Bordetella 10.1371/journal.pone.0006996

Role of DegP for two-partner secretion in Bordetella 10.1111/j.1365-2958.2009.06860.x

Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy 10.1016/j.vaccine.2009.07.075

Genomic island excisions in Bordetella petrii 10.1186/1471-2180-9-141

Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis 10.1016/j.micinf.2009.07.005

Synthetic EthR inhibitors boost antituberculous activity of ethionamide 10.1038/nm.1950

A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice 10.1128/CVI.00082-09

Biomarkers for tuberculosis disease status and diagnosis 10.1097/mcp.0b013e328326f42c

Interaction of the mycobacterial heparin-binding hemagglutinin with actin, as evidenced by single-molecule force spectroscopy 10.1128/JB.00974-08

Origin, spread and demography of the Mycobacterium tuberculosis complex 10.1371/journal.ppat.1000160

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1 10.1016/j.vaccine.2008.08.018

The coiled-coil N-terminal domain of the heparin-binding haemagglutinin is required for the humoral and cellular immune responses in mice 10.1016/j.molimm.2008.07.009

Bordetella pertussis filamentous hemagglutinin delivered by mucosal routes enhances immunoglobulin levels in serum and mucosal fluids 10.1111/j.1574-695x.2008.00460.x

A common vaccination strategy to solve unsolved problems of tuberculosis and pertussis? 10.1016/j.micinf.2008.07.008

How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis 10.1517/14712598.7.11.1665

The peptidyl-prolyl isomerase and chaperone Par27 of Bordetella pertussis as the prototype for a new group of parvulins 10.1016/j.jmb.2007.10.088

Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates 10.1128/IAI.00795-07

Structure-based mechanism of ligand binding for periplasmic solute-binding protein of the Bug family 10.1016/j.jmb.2007.08.006

Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis 10.1371/journal.pone.0000926

Single-molecule force spectroscopy of mycobacterial adhesin-adhesin interactions 10.1128/JB.01299-07

Structure of the membrane protein FhaC: a member of the Omp85-TpsB transporter superfamily 10.1126/science.1143860

In vitro expansion of CD4+CD25highFOXP3+CD127low/- regulatory T cells from peripheral blood lymphocytes of healthy Mycobacterium tuberculosis-infected humans 10.1016/j.micinf.2007.06.004

Regulatory T cells depress immune responses to protective antigens in active tuberculosis 10.1164/rccm.200701-084oc

Macrophage-specific Mycobacterium tuberculosis genes: identification by green fluorescent protein and kanamycin resistance selection 10.1099/mic.0.2006/000547-0

Enzymatic methylation of the Mycobacterium tuberculosis heparin-binding haemagglutinin 10.1111/j.1574-6968.2007.00636.x

Crystal structures of two Bordetella pertussis periplasmic receptors contribute to defining a novel pyroglutamic acid binding DctP subfamily 10.1016/j.jmb.2007.04.047

IL-18 does not increase allergic airway disease in mice when produced by BCG 10.1155/2007/67276

Antibody response in pulmonary tuberculosis against recombinant 27kDa (MPT51, Rv3803c) protein of Mycobacterium tuberculosis 10.1080/00365540701402954

Mycobacterium smegmatis produces an HBHA homologue which is not involved in epithelial adherence 10.1016/j.micinf.2006.11.007

Combined RNAseq and ChIPseq Analyses of the BvgA Virulence Regulator of Bordetella pertussis 10.1128/mSystems.00208-20

Good old BCG – what a century‐old vaccine can contribute to modern medicine 10.1111/joim.13195

The History of Pertussis Toxin 10.3390/toxins13090623

Priscille Brodin

Brodin Priscille

ORCID: 0000-0003-0991-7344

Email: priscille.brodin@inserm.fr

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364

Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z

Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535

Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009

Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163

Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650

High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016

High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24

A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114

Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b

Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040

Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022

A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648

Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779

Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u

The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573

Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675

Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a

High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0

High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044

Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583

High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645

Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507

Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033

Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062

Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064

Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006

Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006

High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06

Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009

Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0

Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049

Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0

CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859

A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x

6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322

Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b

Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681

Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2

Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831

Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029

A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.

Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125

Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025

Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086

Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18

The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030

Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101

Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129

A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627

Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360

Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316

Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902

Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13

Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258

Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18

A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J

Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516

Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127

Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277

Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Worms' Antimicrobial Peptides. 10.3390/md17090512

T(oo)bAd. 10.1038/s41589-019-0347-x

Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Cell microbiology interview 10.1111/cmi.13288

Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505

Anne-Sophie Debrie

Debrie Anne-Sophie

ORCID: 0000-0003-0570-4413

Construction and evaluation of Bordetella pertussis live attenuated vaccine strain BPZE1 producing Fim3. 10.1016/j.vaccine.2018.02.017

Live Attenuated Pertussis Vaccine BPZE1 Protects Baboons Against Bordetella pertussis Disease and Infection. 10.1093/infdis/jix254

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

HBHA vaccination may require both Th1 and Th17 immune responses to protect mice against tuberculosis. 10.1016/j.vaccine.2014.09.024

Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice. 10.1016/j.vaccine.2014.06.019

Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae. 10.1128/cvi.00134-14

Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutinin. 10.1016/j.micinf.2014.04.003

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. 10.1371/journal.pone.0059198

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. 10.1038/ng.2517

Mycobacterial laminin-binding histone-like protein mediates collagen-dependent cytoadherence. 10.1590/s0074-02762012000900025

Seroprevalence of pertussis in Senegal: a prospective study. 10.1371/journal.pone.0048684

Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice. 10.1016/j.vaccine.2012.07.005

Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. 10.4049/jimmunol.1003765

Chips from chips: application to the study of antibody responses to methylated proteins. 10.1021/pr100707t

Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. 10.1016/j.vaccine.2010.08.017

Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. 10.1016/j.vaccine.2010.04.062

Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. 10.1128/cvi.00322-09

In situ chemical modification of peptide microarrays: application to the study of the antibody responses to methylated antigens. 10.1007/978-1-60761-845-4_11

Monocyte-derived interleukin-10 depresses the Bordetella pertussis- specific gamma interferon response in vaccinated infants. 10.1128/cvi.00314-09

Molecular evolution of the two-component system BvgAS involved in virulence regulation in Bordetella. 10.1371/journal.pone.0006996

Cytokine and antibody profiles in 1-year-old children vaccinated with either acellular or whole-cell pertussis vaccine during infancy. 10.1016/j.vaccine.2009.07.075

Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. 10.1016/j.micinf.2009.07.005

Heparin-binding hemagglutinin (HBHA) of Mycobacterium leprae is expressed during infection and enhances bacterial adherence to epithelial cells. 10.1111/j.1574-6968.2009.01488.x

Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. 10.1016/j.vaccine.2008.08.018

Heparin-binding-hemagglutinin-induced IFN-gamma release as a diagnostic tool for latent tuberculosis. 10.1371/journal.pone.0000926

Regulatory T cells depress immune responses to protective antigens in active tuberculosis. 10.1164/rccm.200701-084oc

Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. 10.1371/journal.ppat.0020065

Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation. 10.1016/j.vaccine.2005.01.120

Effector functions of heparin-binding hemagglutinin-specific CD8+ T lymphocytes in latent human tuberculosis. 10.1086/430930

Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. 10.1016/j.micinf.2005.03.023

The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. 10.1128/iai.72.12.6799-6805.2004

Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. 10.1038/nm1090

Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. 10.4049/jimmunol.170.3.1504

Mycobacterial heparin-binding hemagglutinin and laminin-binding protein share antigenic methyllysines that confer resistance to proteolysis. 10.1073/pnas.162246899

Interaction of human Tamm-Horsfall glycoprotein with Bordetella pertussis toxin. 10.1099/00221287-148-4-1193

Nathalie deboosere

deboosere Nathalie

ORCID: 0000-0002-2873-5485

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101

A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227

Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129

Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007

Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013

Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011

Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002

Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10

A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018

Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007

Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015

Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017

Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114

Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4

Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020

Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3

Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005

Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030

Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137

Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364

Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006

How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011

Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z

Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5

[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007

A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j

Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15

Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488

Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650

[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016

Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14

Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040

Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262

The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g

Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u

A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675

High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023

Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a

Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100

High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223

Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645

Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507

Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044

Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583

Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762

Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033

ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07

[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572

Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062

Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064

Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009

Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06

High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05

Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033

An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006

Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541

Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0

Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570

Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009

ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007

Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468

Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004

CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003

Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859

Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x

Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002

Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y

IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551

Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483

Mathias Chamaillard

Chamaillard Mathias

ORCID: 0000-0002-0243-9717

http://phycell.univ-lille.fr/team-2-inflammasome-and-ion-channels

CCL17 Production by Dendritic Cells Is Required for NOD1-mediated Exacerbation of Allergic Asthma 10.1164/rccm.201310-1827OC

Pancreatitis-Associated Protein Does Not Predict Disease Relapse in Inflammatory Bowel Disease Patients 10.1371/journal.pone.0084957

Pseudomonas aeruginosa Type-3 Secretion System Dampens Host Defense by Exploiting the NLRC4-coupled Inflammasome 10.1164/rccm.201307-1358OC

Dysbiosis, a new medical concept 10.1051/medsci/2013296011

Enterocyte loss of polarity and gut wound healing rely upon the F-actin-severing function of villin 10.1073/pnas.1218446110

Looking beyond histological healingin ulcerative colitis: towards the establishment of a molecular signature for quiescent but progressive disease 10.1136/gutjnl-2012-303765

Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice 10.1136/gutjnl-2011-301785

NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer 10.1172/jci62236

The peptide transporter PEPT1 is expressed in distal colon in rodents and humans and contributes to water absorption 10.1152/ajpgi.00491.2012

Intestinally Secreted C-Type Lectin Reg3b Attenuates Salmonellosis but Not Listeriosis in Mice 10.1128/iai.06165-11

Neutralizing responsiveness to Interleukin-33 abrogat1es experimental colitis through enhanced mucosal wound healing 10.1016/j.cyto.2012.06.183

Defensins couple dysbiosis to primary immunodeficiency in Crohn's disease 10.3748/wjg.v17.i5.567

Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury 10.1073/pnas.1100981108

Familial Aggregation and Antimicrobial Response Dose-Dependently Affect the Risk for Crohn's Disease 10.1002/ibd.20985

Lessons from the inflammasome: a molecular sentry linking Candida and Crohn's disease 10.1016/j.it.2010.01.007

Longest Form of CCTG Microsatellite Repeat in the Promoter of the CD2BP1/PSTPIP1 Gene Is Associated with Aseptic Abscesses and with Crohn Disease in French Patients 10.1007/s10620-009-0929-7

Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon 10.1073/pnas.0905745107

Remote Control of Intestinal Tumorigenesis by Innate Immunity 10.1158/0008-5472.can-09-3401

Candida albicans Colonization and ASCA in Familial Crohn's Disease 10.1038/ajg.2009.225

Genetic Variants of Wnt Transcription Factor TCF-4 (TCF7L2) Putative Promoter Region Are Associated with Small Intestinal Crohn's Disease 10.1371/journal.pone.0004496

Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of Yersinia pseudotuberculosis 10.1136/gut.2008.168443

Detection of antisynthetic mannoside antibodies (A Sigma MA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction 10.1111/j.1572-0241.2007.01648.x

NOD2: a potential target for regulating liver injury 10.1038/labinvest.3700716

How NOD2 mutations predispose to Crohn's disease? 10.1016/j.micinf.2007.01.016

IBD serological panels: Facts and perspectives 10.1002/ibd.20226

Involvement of NOD2 signalling in hepatocyte and immune cells during hepatitis 10.1016/s0168-8278(07)61628-6

Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors 10.1038/nm1521

Mesenteric fat in Crohn's disease: A pathogenetic hallmark or an innocent bystander? 10.1136/gut.2005.082925

mu-Opioid receptor activation prevents acute hepatic inflammation and cell death 10.1136/gut.2006.105122

Nod-like receptors: Cytosolic watchdogs for immunity against pathogens 10.1371/journal.ppat.0030152

NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease 10.1177/0968051907080429

Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein 10.1053/j.gastro.2007.06.018

Vascular and cellular stress in inflammatory bowel disease: Revisiting the role of homocysteine 10.1111/j.1572-0241.2007.01170.x

Advances and perspectives in the genetics of inflammatory bowel diseases 10.1053/s1542-3565(05)01096-7

Microbial induction of CARD15 expression in-intestinal epithelial cells via toll-like receptor 5 triggers an antibacterial response loop 10.1002/jcp.20739

Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation 10.1136/gut.2005.080887

NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation 10.1016/j.tim.2006.08.008

PPAR gamma as a new therapeutic in inflammatory bowel diseases 10.1136/gut.2006.093484

A novel caspase-1/toll-like receptor 4-independent pathway of cell death induced by cytosolic Shigella in infected macrophages 10.1074/jbc.M414671200

NOD-LRR proteins: Role in host-microbial interactions and inflammatory disease 10.1146/annurev.biochem.74.082803.133347

Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract 10.1126/science.1104911

Battling enteroinvasive bacteria: Nod1 comes to the rescue 10.1016/j.tim.2004.10.001

Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition 10.1038/sj.emboj.7600175

Regulatory role of Nod2 in intestinal immunity 10.1016/s0399-8320(04)95209-8

An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid 10.1038/ni945

Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon 10.1136/gut.52.6.840

CARD4/NOD1 is not involved in inflammatory bowel disease 10.1136/gut.52.1.71

Clustering of Crohn's disease within affected sibships 10.1038/sj.ejhg.5200932

Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases 10.1073/pnas.0530276100

Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection 10.1074/jbc.C200651200

Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation 10.1046/j.1462-5822.2003.00304.x

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease 10.1038/35079107

CARD15 mutations in Blau syndrome 10.1038/ng720

Genetic refinement and physical mapping of a chromosome 16q candidate region for inflammatory bowel disease 10.1038/sj.ejhg.5200710

Globin genes in Guadeloupe: vestige of slavery 10.1016/s0369-8114(01)00198-5

Genetic analyses of chromosome 12 loci in Crohn's disease 10.1136/gut.47.6.787

A dietary flavone confers communicable protection against colitis through NLRP6 signaling independently of inflammasome activation 10.1038/mi.2017.87

Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence 10.1136/gutjnl-2017-314195

Integrin a6 loss promotes colitis-associated colorectal cancer. Response to: "Integrin a6 variants and colorectal cancer" by Beaulieu JF 10.1136/gutjnl-2017-315727 10.1136/gutjnl-2017-315727.

MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype 10.1073/pnas.1722372115

Understanding the Cellular Origin of the Mononuclear Phagocyte System Sheds Light on the Myeloid Postulate of immune Paralysis in Sepsis 10.3389/fimmu.2018.00823

Effects of enteral polymeric diet on gut microbiota in children with Crohn's disease 10.1136/gutjnl-2015-311058

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota 10.1080/2162402x.2015.1132137

Genetic Factors Interact With Tobacco Smoke to Modify Risk for Inflammatory Bowel Disease in Humans and Mice 10.1053/j.gastro.2017.05.010

Hemidesmosome integrity protects the colon against colitis and colorectal cancer 10.1136/gutjnl-2015-310847

Intestinal microbiota: what to expect physiologically and therapeutically? 10.1016/j.therap.2017.01.001

Keeping the (S)toolbox Alive Outside of the Body for Drugs Discovery 10.1053/j.gastro.2017.10.022 10.1053/j.gastro.2017.10.022.

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619

The battlefield in the war against attaching-and-effacing bacterial pathogens: Monocytes, macrophages and dendritic cells in action 10.1016/j.vetmic.2016.09.007

The human gut microbiome as source of innovation for health: Which physiological and therapeutic outcomes could we expect? 10.1016/j.therap.2016.12.007

Type I interferons drive inflammasome-independent emergency monocytopoiesis during endotoxemia 10.1038/s41598-017-16869-2

A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies 10.1016/j.ajhg.2016.02.025

Defining dysbiosis threatens Koch's postulates and current dogma on the role of Paneth cells in Crohn's disease 10.1136/gutjnl-2015-309333

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects 10.1016/j.immuni.2016.09.009

Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation 10.1016/j.celrep.2016.07.054

Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome 10.1158/0008-5472.can-16-0448

NOD2 gene variant is a risk factor for postoperative complications in patients with Crohn's disease: A genetic association study 10.1016/j.surg.2016.01.013

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors 10.1016/j.immuni.2016.06.001

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota 10.1126/science.aad1329

CARD8 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease 10.1016/j.dld.2015.07.013

Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation 10.1093/jmcb/mjy012

Gut microbiome and anticancer immune response: really hot Sh(star)t! 10.1038/cdd.2014.56

Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth 10.1038/ncb3206

Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions 10.1586/1744666x.2015.1032256

Photodynamic Therapy Relieves Colitis and Prevents Colitis-associated Carcinogenesis in Mice 10.1097/mib.0000000000000354

Time for epithelial sensing of vitamin D to step into the limelight 10.1136/gutjnl-2014-308119

Role of NLRs in the Regulation of Type I Interferon Signaling, Host Defense and Tolerance to Inflammation 10.3390/ijms22031301

Romain Veyron-Churlet

Veyron-Churlet Romain

ORCID: 0000-0001-6902-5917

ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371

Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297

LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619

Synthetic variants of mycolactone bind and activate Wiskott-Aldrich syndrome proteins. 10.1021/jm5008819

Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis. 10.1371/journal.ppat.1004115

A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114

Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis. 10.1038/nchembio.1277

The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes. 10.1371/journal.pone.0029564

Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. 10.1172/jci66576

Expression of OmpATb is dependent on small membrane proteins in Mycobacterium bovis BCG. 10.1016/j.tube.2011.06.008

Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring. 10.1371/journal.pntd.0001237

Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis. 10.1111/j.1365-2958.2010.07446.x

Phosphorylation of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. 10.1074/jbc.m110.105189

The Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue. 10.1074/jbc.m806537200

The Mycobacterium tuberculosis serine/threonine kinase PknL phosphorylates Rv2175c: mass spectrometric profiling of the activation loop phosphorylation sites and their role in the recruitment of Rv2175c. 10.1002/pmic.200700442

The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. 10.1016/j.jmb.2005.09.016

Protein-protein interactions within the Fatty Acid Synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. 10.1111/j.1365-2958.2004.04334.x

Rv0613c/MSMEG_1285 Interacts with HBHA and Mediates Its Proper Cell-Surface Exposure in Mycobacteria 10.3390/ijms19061673

In Vivo Methods to Study Protein-Protein Interactions as Key Players in Mycobacterium Tuberculosis Virulence. 10.3390/pathogens8040173

Protein scaffold involving MSMEG_1285 maintain cell wall organization and mediates penicillin sensitivity in mycobacteria. 10.1111/febs.15232

In Vivo Methods to Study Protein-Protein Interactions as Key Players in Mycobacterium tuberculosis Virulence 10.20944/preprints201908.0309.v1

Interconnection of the mycobacterial heparin-binding hemagglutinin with cholesterol degradation and heme/iron pathways identified by proximity-dependent biotin identification in Mycobacterium smegmatis. 10.1111/1462-2920.15547